These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33468927)

  • 1. [Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
    Nakatsukasa R; Hata T; Hayashi N; Urabe S; Hayashi K; Nakagawa T; Michiura T; Yamabe K
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2260-2262. PubMed ID: 33468927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
    Kagawa Y; Inoue A; Nishizawa Y; Kawai K; Ohta T; Hata T; Naito A; Komatsu H; Miyazaki Y; Tomokuni A; Motoori M; Fujitani K; Kato T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1819-1821. PubMed ID: 35046341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Int J Clin Oncol; 2011 Dec; 16(6):766-9. PubMed ID: 21560034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy].
    Murata A; Inoue T; Maeda K; Noda E; Nagahara H; Kubo N; Tanaka H; Muguruma K; Yamada N; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2623-5. PubMed ID: 21224659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laparoscopic-assisted one-stage resection of rectal cancer with synchronous liver metastasis utilizing a pfannenstiel incision.
    Aljiffry M; Alrajraji M; Al-Sabah S; Hassanain M
    Saudi J Gastroenterol; 2014; 20(5):315-8. PubMed ID: 25253368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of locally advanced rectal cancer responding to FOLFOX].
    Kume S; Kubota T; Takahashi M; Hashimoto D; Hirata T; Torigoe Y; Ikeda O
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):659-61. PubMed ID: 19381043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
    Huh JW; Kim YJ; Kim HR
    World J Gastroenterol; 2009 Feb; 15(6):756-7. PubMed ID: 19222104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.
    Park JM; Chi KC
    World J Surg Oncol; 2010 Dec; 8():109. PubMed ID: 21167074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
    Yasuda T; Tanaka O; Hayashi S; Nakahata Y; Yasuda Y; Omatsu T; Obora A; Kojima T; Matsuo M; Yagi N
    Clin J Gastroenterol; 2020 Feb; 13(1):11-16. PubMed ID: 31321737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
    Mitsuhashi K; Matsusaka S; Mizunuma N; Ichimura T; Ozaka M; Ogura M; Shinozaki E; Suenaga M; Chin K; Fujimoto Y; Saiura A; Yamamoto N; Hatake K
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2203-7. PubMed ID: 21084828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
    Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4.
    Dzunic M; Andjelkovic-Apostolovic M; Vrbic S; Pejcic I; Petkovic I; Cvetanovic A; Dinic S
    J BUON; 2020; 25(1):212-219. PubMed ID: 32277634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX].
    Yamazoe S; Yamaguchi K; Terasawa H; Ojima T; Tsujimura H; Shimomura T
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):125-8. PubMed ID: 21368473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.